Therapeutic effect of the O-linked N-acetylglucosamine transferase inhibitor HLY838 on liver cancer：a study based on the Sleeping Beauty transposition system

Liang Huijun; Huang Luyi; Wang Kai; Tang Ni

doi:10.13406/j.cnki.cyxb.003637

您当前的位置：

首页 >

文章列表页 >

Therapeutic effect of the O-linked N-acetylglucosamine transferase inhibitor HLY838 on liver cancer：a study based on the Sleeping Beauty transposition system

Basic research | 更新时间：2025-10-23

- Therapeutic effect of the O-linked N-acetylglucosamine transferase inhibitor HLY838 on liver cancer：a study based on the Sleeping Beauty transposition system
- Journal of Chongqing Medical University Vol. 50, Issue 1, Pages: 30-36(2025)
- 作者机构：
  
  重庆医科大学感染性疾病分子生物学教育部重点实验室，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003637
  CLC： R735.7
- Received：26 June 2024，
  
  Revised：2024-08-12，
  
  Accepted：10 October 2024，
  
  Published：28 January 2025
- 稿件说明：
移动端阅览
梁惠钧,黄露义,汪凯,等.基于“睡美人”转座系统观察OGT抑制剂HLY838对肝癌的治疗作用[J].重庆医科大学学报,2025,50(1):30-36.

Liang Huijun,Huang Luyi,Wang Kai,et al.Therapeutic effect of the O-linked N-acetylglucosamine transferase inhibitor HLY838 on liver cancer：a study based on the Sleeping Beauty transposition system[J].Journal of Chongqing Medical University,2025,50(1):30-36.
梁惠钧,黄露义,汪凯,等.基于“睡美人”转座系统观察OGT抑制剂HLY838对肝癌的治疗作用[J].重庆医科大学学报,2025,50(1):30-36. DOI： 10.13406/j.cnki.cyxb.003637.

Liang Huijun,Huang Luyi,Wang Kai,et al.Therapeutic effect of the O-linked N-acetylglucosamine transferase inhibitor HLY838 on liver cancer：a study based on the Sleeping Beauty transposition system[J].Journal of Chongqing Medical University,2025,50(1):30-36. DOI： 10.13406/j.cnki.cyxb.003637.

摘要

目的

利用“睡美人”转座系统和快速大容量尾静脉注射法，建立肝癌动物模型，并观察O-连接N-乙酰氨基葡萄糖转移酶（O-linked N-acetylglucosamine transferase，OGT）抑制剂（R）-3-（2-甲氧基苯基）-1-（噻吩-2-基甲基）哌嗪-2，5-二酮［（R）-3-（2methoxyphenyl）-1-（thiophen-2-ylmethyl）piperazine-2，5dione，HLY838］对肝癌的治疗效果。

方法

将6～8周龄雄性C57BL/6J小鼠随机分为3组，分别将插入神经母细胞瘤ras病毒同源物（neuroblastoma RAS viraloncogene homolog，NRAS）的NRASV12转座子质粒、表达β-连环蛋白（β-catenin）基因转座子质粒、表达Yes相关蛋白（Yes-associated protein，YAP）基因的转座子质粒pT3-EF1aH Yap S127A与转座酶SB100质粒的混合溶液经尾静脉快速注射至小鼠体内，饲养8～16周后处死小鼠，观察肝脏成瘤情况以及肝脏病理学变化。肝癌模型建成后，腹腔注射HLY838，观察对肝癌的治疗效果。

结果

高压注射质粒8～16周后，小鼠肝脏体积增大，表面出现颗粒状、结节样改变；苏木精-伊红染色（hematoxylin-eosin staining，HE）染色显示肝组织结构紊乱，出现多个肿瘤结节。pT3-EF1aH YAP S127A组成瘤率高、时间短，但肿瘤较小；pT/CAGGS-NrasV组肿瘤结节大小适中，但成瘤时间较长；pT3-N90-β-catenin组肿瘤主要为肝细胞癌。HLY838治疗组小鼠肝肿瘤结节数变少，小鼠肝肿瘤负担减轻。

结论

应用水动力大容量尾静脉注射质粒的方法可快速建立小鼠肝癌模型，成功率较高。OGT抑制剂HLY838对小鼠肝癌有较好的抗肿瘤效果。

Abstract

Objective

To establish an animal model of liver cancer by rapid high-volume tail vein injection，and to investigate the therapeutic effect of O-linked N-acetylglucosamine transferase inhibitor（R）-3-（2methoxyphenyl）-1-（thiophen-2-ylmethyl）piperazine-2，5dione（HLY838） on liver cancer based on the Sleeping Beauty（SB） transposition system.

Methods

Male C57BL/6J mice，aged 6-8 weeks，were randomly divided into three groups and were given the NRASV12 transposon plasmid，the β-catenin gene-expressing transposon plasmid，or the YAP gene-expressing transposon plasmid pT3-EF1aH Yap S127A，mixed with the transposase SB100 plasmid，through rapid high-volume tail vein injection. The mice were sacrificed after 8-16 weeks of feeding to observe tumor formation and liver pathological changes. After the establishment of the liver cancer model，HLY838 was injected intraperitoneally to investigate its therapeutic effect on liver cancer.

Results

After high-pressure injection of the plasmids for 8-16 weeks，there was an increase in liver volume，with granular and nodular changes on the surface of the liver，and HE staining showed disordered structure of the liver and the presence of multiple tumor nodules. The pT3-EF1aH YAP S127A group had a higher tumor formation rate and a shorter duration，but with a relatively small tumor size；the pT/CAGGS-NrasV group had moderately sized tumor nodules，but with a relative long time for tumor formation； the pT3-N90-β-catenin group mainly had hepatocellular carcinoma. The HLY838 treatment group had reductions in the number of liver tumor nodules and the burden of liver tumor.

Conclusion

The method of hydrodynamic high-volume tail vein injection can be used to establish a mouse model of liver cancer rapidly，with a relatively high success rate. The OGT inhibitor HLY838 has a good antitumor effect on liver cancer in mice.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 ．

Noij DP ， van Der Linden PWG . Spontaneous regression of hepatocellular carcinoma in a Caucasian male patient：a case report and review of the literature [J ] . Mol Clin Oncol ， 2017 ， 6 （ 2 ）： 225 - 228 ．

Romualdo GR ， Grassi TF ， Goto RL ， et al . An integrative analysis of chemically-induced cirrhosis-associated hepatocarcinogenesis：Histological，biochemical and molecular features [J ] . Toxicol Lett ， 2017 ， 281 ： 84 - 94 ．

Reiberger T ， Chen Y ， Ramjiawan RR ， et al . An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis [J ] . Nat Protoc ， 2015 ， 10 （ 8 ）： 1264 - 1274 ．

Sandoval-Villegas N ， Nurieva W ， Amberger M ， et al . Contemporary transposon tools：a review and guide through mechanisms and applications of Sleeping beauty ， piggyBac and Tol2 for genome engineering [J ] . Int J Mol Sci ， 2021 ， 22 （ 10 ）： 5084 ．

Saha A ， Bello D ， Fernández-Tejada A . Advances in chemical probing of protein O -GlcNAc glycosylation：structural role and molecular mechanisms [J ] . Chem Soc Rev ， 2021 ， 50 （ 18 ）： 10451 - 10485 ．

Hart GW . Nutrient regulation of signaling and transcription [J ] . J Biol Chem ， 2019 ， 294 （ 7 ）： 2211 - 2231 ．

Zhu Y ， Hart GW . Targeting O-GlcNAcylation to develop novel therapeutics [J ] . Mol Aspects Med ， 2021 ， 79 ： 100885 ．

Zhu Q ， Wang HX ， Chai SY ， et al . O -GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation [J ] . Proc Natl Acad Sci USA ， 2023 ， 120 （ 13 ）： e2216796120 ．

Chen X ， Calvisi DF . Hydrodynamic transfection for generation of novel mouse models for liver cancer research [J ] . Am J Pathol ， 2014 ， 184 （ 4 ）： 912 - 923 ．

Tang M ， Zhao Y ， Zhao JH ， et al . Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes [J ] . Sci Adv ， 2022 ， 8 （ 25 ）： eabn5683 ．

Shan XQ ， Jiang R ， Gou DM ， et al . Identification of a diketopiperazine-based O-GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition [J ] . FEBS J ， 2023 ， 290 （ 18 ）： 4543 - 4561 ．

Very N ， Vercoutter-Edouart AS ， Lefebvre T ， et al . Cross-dysregulation of O -GlcNAcylation and PI3K/AKT/mTO R axis in human chronic diseases [J ] . Front Endocrinol （Lausanne）， 2018 ， 9 ： 602 ．

Raab S ， Gadault A ， Very N ， et al . Dual regulation of fatty acid synthase （FASN） expression by O-GlcNAc transferase （OGT） and mTOR pathway in proliferating liver cancer cells [J ] . Cell Mol Life Sci ， 2021 ， 78 （ 13 ）： 5397 - 5413 ．

Olson B ， Li YD ， Lin Y ， et al . Mouse models for cancer immunotherapy research [J ] . Cancer Discov ， 2018 ， 8 （ 11 ）： 1358 - 1365 ．

May M . Cancer research with a human touch [J ] . Nature ， 2018 ， 556 （ 7700 ）： 259 - 261 ．

Boehme P ， Doerner J ， Solanki M ， et al . The sleeping beauty transposon vector system for treatment of rare genetic diseases：an unrealized hope? [J ] . Curr Gene Ther ， 2015 ， 15 （ 3 ）： 255 - 265 ．

Asquith CRM ， Temme L . STK19：a new target for NRAS-driven cancer [J ] . Nat Rev Drug Discov ， 2020 ， 19 （ 9 ）： 579 ．

Zhang MQ ， Pan JC ， Huang P . Interaction between RAS gene and lipid metabolism in cancer [J ] . J Zhejiang Univ Med Sci ， 2021 ， 50 （ 1 ）： 17 - 22 ．

Ni CJ ， Qin XS ， Huang ZS . Role of Wnt/β-catenin signaling pathway in occurrence and development of hepatocellular carcinoma [J ] . World Chin J Dig ， 2021 ， 29 （ 4 ）： 190 - 196 ．

Ozcan M ， Altay O ， Lam S ， et al . Improvement in the current therapies for hepatocellular carcinoma using a systems medicine approach [J ] . Adv Biosyst ， 2020 ， 4 （ 6 ）： e2000030 ．

Zhu H ， Yan FJ ， Yuan T ， et al . USP10 promotes proliferation of hepatocellular carcinoma by deubiquitinating and stabilizing YAP/TAZ [J ] . Cancer Res ， 2020 ， 80 （ 11 ）： 2204 - 2216 ．

Juan WC ， Hong WJ . Targeting the hippo signaling pathway for tissue regeneration and cancer therapy [J ] . Genes ， 2016 ， 7 （ 9 ）： 55 ．

Moya IM ， Halder G . Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine [J ] . Nat Rev Mol Cell Biol ， 2019 ， 20 （ 4 ）： 211 - 226 ．

Ho C ， Wang CM ， Mattu S ， et al . AKT （v-akt murine thymoma viral oncogene homolog 1） and N-Ras （neuroblastoma ras viral oncogene homolog） coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR（mammalian target of rapamycin complex 1），FOXM1 （forkhead box M1）/SKP2，and c-Myc pathways [J ] . Hepatology ， 2012 ， 55 （ 3 ）： 833 - 845 ．

Sun RQ ， Zhang ZY ， Bao RX ， et al . Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis [J ] . J Hepatol ， 2022 ， 77 （ 2 ）： 453 - 466 ．

Zhang N ， Jiang HL ， Zhang KX ， et al . OGT as potential novel target：structure，function and inhibitors [J ] . Chem Biol Interact ， 2022 ， 357 ： 109886 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Etablishment and evaluation standards of skin photoaging model in SD rat

Animal model of arteriovenous fistula combined with chronic renal failure in New Zealand white rabbits

Establishment of Chinese rural dog intrauterine adhesion model by mechanical and infection double injury

EXPERIMENTAL AND CLINICAL STUDY ON CRYPTOSPORIDIOSIS II. CRYPTOSPORIDIUM IN DIFFERENT IMMUNOSUPPRESSIVE ANIMALS

Related Author

Fu Qiang

Ke Yiling

He Guiqiong

Yu Huarong

Cao Di

Chen Jin

Huang Kun

Fang Sheng

Related Institution

Center for Neuroscience Research，Chongqing Medical University

Department of Dermatology,The First Affiliated Hospital of Chongqing Medical University

Department of Vascular Surgery,The First Affiliated Hospital of Chongqing Medical University

Department of Gynaecology and Obstetrics,University Town Hospital of Chongqing Medical University

重庆医科大学传染病寄生虫病研究所

⁰